9. Precigen Inc. (NASDAQ:PGEN)
Number of Hedge Fund Holders: 27
Market Capitalization: $2.20 billion
Share Price: $6.15
Precigen, Inc. (NASDAQ: PGEN) offers something that many emerging biotechnology companies are still working toward: an approved product generating meaningful revenue and a profitable quarter. Its shares had gained approximately 46% in 2026, according to the supplied figures, as investors responded to the commercial rollout of PAPZIMEOS.
The treatment addresses recurrent respiratory papillomatosis, or RRP, a disease associated with recurring growths in the respiratory tract. PAPZIMEOS is designed to generate an immune response against proteins from the human papillomavirus types underlying the condition, giving the company a differentiated position in a market historically reliant on repeated procedures.
Commercial results have been substantial. PAPZIMEOS generated $74.7 million in revenue during the first half of 2026, including $53.1 million in the second quarter. Quarterly sales more than doubled sequentially, helping produce net income of $20.1 million, compared with a $26.6 million loss a year earlier.
That transition changes the questions investors need to ask. Clinical potential remains relevant, but patient enrollment, physician adoption, insurance coverage, and the durability of demand now carry greater weight in assessing future earnings.
The company reported seven years of FDA-granted market exclusivity for PAPZIMEOS and broad U.S. payer coverage. International expansion and additional applications of its AdenoVerse platform could widen the opportunity, although each development program carries its own requirements.
Cash, cash equivalents, and investments totaled $38.7 million at June 30. Management expected existing resources and product receipts to support operations through cash-flow break-even by year-end.
Ranking rationale: Precigen, Inc. (NASDAQ: PGEN) takes ninth place with 27 hedge-fund holders, tying the next entry on ownership count. Its commercial revenue growth and return to quarterly profitability distinguish it from development-stage biotech stocks that remain dependent on future approvals.
